Wonik Past Earnings Performance
Past criteria checks 1/6
Wonik's earnings have been declining at an average annual rate of -37.9%, while the Healthcare industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 11.8% per year. Wonik's return on equity is 10.3%, and it has net margins of 19.7%.
Key information
-37.90%
Earnings growth rate
-37.92%
EPS growth rate
| Healthcare Industry Growth | 34.17% |
| Revenue growth rate | 11.85% |
| Return on equity | 10.35% |
| Net Margin | 19.66% |
| Last Earnings Update | 30 Sep 2025 |
Recent past performance updates
Shareholders In Wonik (KOSDAQ:032940) Should Look Beyond Earnings For The Full Story
Nov 21
There May Be Underlying Issues With The Quality Of Wonik's (KOSDAQ:032940) Earnings
Apr 01Are Wonik's (KOSDAQ:032940) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 03
Recent updates
Shareholders In Wonik (KOSDAQ:032940) Should Look Beyond Earnings For The Full Story
Nov 21The Market Lifts Wonik Corporation (KOSDAQ:032940) Shares 40% But It Can Do More
Oct 27The Returns On Capital At Wonik (KOSDAQ:032940) Don't Inspire Confidence
Oct 24Is Wonik (KOSDAQ:032940) Using Too Much Debt?
Aug 28Slammed 32% Wonik Corporation (KOSDAQ:032940) Screens Well Here But There Might Be A Catch
Jul 31Returns On Capital At Wonik (KOSDAQ:032940) Paint A Concerning Picture
Jul 23Fewer Investors Than Expected Jumping On Wonik Corporation (KOSDAQ:032940)
May 29There May Be Underlying Issues With The Quality Of Wonik's (KOSDAQ:032940) Earnings
Apr 01Market Might Still Lack Some Conviction On Wonik Corporation (KOSDAQ:032940) Even After 35% Share Price Boost
Feb 21Market Might Still Lack Some Conviction On Wonik Corporation (KOSDAQ:032940) Even After 35% Share Price Boost
Feb 21The Market Doesn't Like What It Sees From Wonik Corporation's (KOSDAQ:032940) Revenues Yet
Nov 01Is Wonik (KOSDAQ:032940) A Risky Investment?
Aug 12Wonik Corporation's (KOSDAQ:032940) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Jun 18Estimating The Fair Value Of Wonik Corporation (KOSDAQ:032940)
May 21I Ran A Stock Scan For Earnings Growth And Wonik (KOSDAQ:032940) Passed With Ease
May 03Reflecting on Wonik's (KOSDAQ:032940) Share Price Returns Over The Last Five Years
Feb 21Is Wonik (KOSDAQ:032940) A Risky Investment?
Jan 25Wonik Corporation (KOSDAQ:032940) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Dec 29Are Wonik's (KOSDAQ:032940) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 03Revenue & Expenses Breakdown
How Wonik makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 25 | 149,958 | 29,474 | 58,377 | 1,530 |
| 30 Jun 25 | 143,855 | 26,555 | 57,356 | 1,513 |
| 31 Mar 25 | 141,230 | 27,885 | 57,007 | 1,503 |
| 31 Dec 24 | 138,735 | 21,142 | 56,050 | 1,237 |
| 30 Sep 24 | 138,819 | -3,680 | 56,658 | 1,285 |
| 30 Jun 24 | 137,116 | -6,310 | 53,601 | 1,221 |
| 31 Mar 24 | 132,341 | -8,091 | 51,572 | 1,182 |
| 31 Dec 23 | 129,877 | -1,724 | 48,728 | 1,210 |
| 30 Sep 23 | 126,785 | 21,617 | 47,094 | 1,169 |
| 30 Jun 23 | 121,338 | 28,231 | 45,331 | 1,125 |
| 31 Mar 23 | 114,991 | 36,035 | 42,813 | 1,117 |
| 31 Dec 22 | 108,089 | 38,242 | 40,324 | 1,064 |
| 30 Sep 22 | 103,238 | 22,595 | 39,320 | 919 |
| 30 Jun 22 | 97,617 | 19,598 | 36,872 | 972 |
| 31 Mar 22 | 94,358 | 24,858 | 33,531 | 849 |
| 31 Dec 21 | 94,675 | 28,488 | 32,708 | 726 |
| 30 Sep 21 | 90,396 | 121,603 | 31,114 | 671 |
| 30 Jun 21 | 91,787 | 112,407 | 30,677 | 462 |
| 31 Mar 21 | 91,060 | 120,585 | 29,569 | 398 |
| 31 Dec 20 | 87,494 | 79,391 | 30,242 | 355 |
| 30 Sep 20 | 91,501 | 1,424 | 32,786 | -27 |
| 30 Jun 20 | 90,880 | 8,069 | 35,155 | -15 |
| 31 Mar 20 | 90,669 | -24,193 | 38,099 | -9 |
| 31 Dec 19 | 90,386 | 36,563 | 39,436 | 0 |
| 30 Sep 19 | 88,331 | -64,905 | 40,648 | 243 |
| 30 Jun 19 | 86,999 | -66,368 | 40,154 | 182 |
| 31 Mar 19 | 82,848 | -48,438 | 38,662 | 93 |
| 31 Dec 18 | 80,295 | -69,664 | 36,648 | 0 |
| 30 Sep 18 | 79,894 | 18,426 | 36,517 | 0 |
| 30 Jun 18 | 76,251 | 19,025 | 33,488 | 0 |
| 31 Mar 18 | 70,638 | 18,011 | 29,779 | 0 |
| 31 Dec 17 | 67,244 | 13,787 | 27,606 | 0 |
| 30 Sep 17 | 60,466 | 7,125 | 21,398 | 0 |
| 30 Jun 17 | 60,936 | 76,804 | 21,190 | 0 |
| 31 Mar 17 | 62,986 | 72,178 | 20,736 | 0 |
| 31 Dec 16 | 64,804 | 70,649 | 20,770 | 0 |
| 30 Sep 16 | 80,201 | 72,050 | 23,151 | 0 |
| 30 Jun 16 | 73,943 | -67 | 22,270 | 0 |
| 31 Mar 16 | 60,012 | 209 | 18,518 | 0 |
| 31 Dec 15 | 59,528 | -875 | 17,124 | 0 |
| 31 Dec 14 | 56,839 | 239 | 11,666 | 0 |
Quality Earnings: A032940 has a large one-off gain of ₩10.4B impacting its last 12 months of financial results to 30th September, 2025.
Growing Profit Margin: A032940 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A032940's earnings have declined by 37.9% per year over the past 5 years.
Accelerating Growth: A032940 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A032940 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (3.4%).
Return on Equity
High ROE: A032940's Return on Equity (10.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/28 19:25 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wonik Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.